JAMIE GEIER: Open Payments
NPI 1417358672 · ANDOVER, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,089 in 119 payments from 28 companies in 2025. Trend: 2023 $1,224 · 2024 $2,049 · 2025 $2,089
Food & beverage: $2,089
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $261 |
| Lilly USA, LLC | 11 | $196 |
| Amgen Inc. | 14 | $192 |
| PFIZER INC. | 14 | $175 |
| Vanda Pharmaceuticals Inc. | 4 | $116 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $110 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $103 |
| Dexcom, Inc. | 5 | $91 |
| Lundbeck LLC | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
Products named: REXULTI, MOUNJARO, FANAPT, FARXIGA, CAPLYTA, OTEZLA, Kerendia, Dexcom G6 Transmitter.
Industry payments across KS — which companies pay providers there.
